Key Points:

• Retension Pharmaceuticals and TRex Bio are positioned to bring roughly $176 million of potential gross IPO value to Nasdaq, making biotechnology the clearest source of fresh U.S. equity issuance on October 8.
• TRex Bio is seeking up to $133.3 million from 8.3 million shares at $14 to $16, while Retension is offering 3.3 million shares at $11 to $13, highlighting continued investor access for clinical-stage companies.
• The broader calendar shows only three expected events, but all three relate to Southern Cross Acquisition II securities separating from an existing SPAC unit, underscoring how headline IPO counts can overstate conventional new issuance.

Biotech Emerges as the Clearest IPO Growth Segment

The U.S. IPO market enters October 8 with a narrow but meaningful pocket of activity. Retension Pharmaceuticals and TRex Bio are both preparing Nasdaq offerings, creating roughly $176 million of potential gross issuance based on the upper ends of their announced ranges. At the same time, the day’s headline calendar lists three expected events for Southern Cross Acquisition II, but those securities are being separated from units that already began trading in August rather than representing a new operating-company IPO.

TRex Bio Leads the Day’s New Equity Supply

TRex Bio represents the larger of the two operating-company offerings. The clinical-stage biotechnology company is marketing approximately 8.3 million shares at $14 to $16 each, potentially raising as much as $133.3 million at the top of the range. The company plans to list on the Nasdaq Global Select Market under TRXB.

The offering is significant not simply because of its size but because of the type of company accessing the market. TRex is developing therapies for autoimmune and inflammatory diseases, with proceeds intended to support the clinical development of its drug candidates. Eli Lilly has also indicated interest in purchasing shares in the IPO, subject to a limit on its resulting ownership. That provides an additional institutional signal around the transaction, although the final pricing and aftermarket performance remain the more important tests of public-market demand.

Retension Offers a Smaller Test of Biotech Demand

Retension Pharmaceuticals is pursuing a smaller Nasdaq IPO, offering 3.3 million shares at $11 to $13. The latest SEC filing confirms the offering structure and says the company has applied to list under RTSN. At the midpoint of the range, the company expects approximately $33.8 million in net proceeds after offering expenses, before any exercise of the underwriters’ option.

Retension is developing RTN-001, a once-daily oral treatment for uncontrolled and resistant hypertension. The company is still clinical-stage and has not generated product revenue, meaning the IPO is primarily a financing event for continued development rather than an offering backed by an established commercial business. Its ability to proceed alongside the larger TRex transaction nevertheless suggests that investors remain willing to fund selected biotechnology programs even as other sectors face a more difficult IPO environment.

SPAC Activity Inflates the October 8 Calendar

The three Southern Cross Acquisition II entries require a different interpretation. The company announced that holders of 7,652,630 units sold in its August IPO can begin separating the units into ordinary shares, warrants and rights. Those securities will trade separately under SCAT, SCATW and SCATR, while unsplit units continue under SCATU.

Southern Cross had already raised $76.5 million through its August unit offering. The October 8 activity therefore represents a restructuring of securities from an existing SPAC transaction rather than another fresh operating-company capital raise.

Biotech Demand Contrasts With Broader IPO Caution

The distinction is increasingly important for assessing the health of the U.S. IPO market. Recent market reporting indicates that biotechnology has been one of the strongest areas of new issuance in 2026, with 23 biotech companies going public during the first three quarters, nearly three times the number recorded throughout 2025. About 65% of the year’s biotech IPOs were trading above their offer prices, compared with 37.5% for the 2025 cohort.

That performance helps explain why clinical-stage biotechnology companies continue to find a public-market window while larger technology transactions have faced greater valuation scrutiny and postponements. The contrast with Oura’s delayed offering is particularly relevant: investors have not abandoned IPOs broadly, but appear to be differentiating more sharply between sectors, business models and valuation expectations.

What the IPO Market Is Watching Next

The immediate test is whether Retension and TRex can price successfully and establish stable trading after listing. Strong execution would reinforce the view that the IPO market remains selectively open, particularly for biotechnology, while weak aftermarket performance would add to valuation concerns across new issuance. Investors should also distinguish genuine primary equity supply from SPAC security activity and other technical listings when assessing whether U.S. IPO momentum is actually broadening.